MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
MBX Biosciences (Nasdaq: MBX) reported Q4 and full-year 2025 results and clinical progress on March 12, 2026. Key clinical milestones include an FDA End-of-Phase 2 meeting and a Phase 3 start for once-weekly canvuparatide on track for Q3 2026, plus obesity candidate nominations in Q2–Q3 2026.
Pro forma cash and investments totaled $459.1 million as of Dec 31, 2025, expected to fund operations into 2029; 2025 net loss was $87.0 million.
Positive
- Pro forma cash of $459.1M expected to fund operations into 2029
- Phase 3 initiation for once-weekly canvuparatide on track for Q3 2026
- 12-week MAD data for MBX 4291 due Q4 2026
Negative
- Net loss increased to $87.0M in 2025 from $61.9M in 2024
- R&D spend rose to $79.2M in 2025 from $57.4M in 2024 (+38%)
- G&A expenses rose to $18.9M in 2025 from $10.8M in 2024 (+75%)
News Market Reaction – MBX
On the day this news was published, MBX declined 3.42%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.5% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $44M from the company's valuation, bringing the market cap to $1.25B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MBX slipped 0.24% with subdued volume, while close biotech peers showed a mixed tape (some up, some down) and none triggered momentum scanner signals, pointing to a stock-specific reaction.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Positive | +9.7% | Positive Phase 2 canvuparatide data and ~$391.7M cash, runway into 2029. |
| Aug 07 | Q2 2025 earnings | Neutral | -4.6% | Strong cash position with launch of key trials and higher R&D and net loss. |
| May 12 | Q1 2025 earnings | Neutral | +0.3% | Robust cash, higher operating expenses, and Avail Phase 2 nearing topline data. |
| Mar 17 | FY 2024 earnings | Neutral | +1.7% | Pipeline progress, increased 2024 R&D and G&A, and runway into mid-2027. |
| Nov 07 | Q3 2024 earnings | Neutral | +2.1% | IPO and Series C funding, solid cash, and advancing Phase 1/2 programs. |
Earnings updates have generally been received steadily to positively, with prior reactions clustering around modest single-digit moves, often aligned with constructive pipeline and cash runway commentary.
Over the past five earnings cycles from Nov 2024 to Nov 2025, MBX repeatedly highlighted growing cash balances, extended runway into 2027–2029, and steady advancement of canvuparatide, MBX 4291, and imapextide. Price reactions ranged from slightly negative to strongly positive, with most events showing aligned moves on continued clinical progress and financing. Today’s report continues this pattern with strengthened liquidity and clear late-stage plans, fitting into a consistent execution narrative.
Historical Comparison
In the last five earnings releases, MBX’s average move was about 1.83%, with mostly aligned reactions to steady cash runway and pipeline progress. Today’s slight dip of 0.24% sits well within that historical range.
Earnings updates show a clear progression: cash runway extended from mid-2027 to 2029 while canvuparatide advanced from Phase 2 Avail™ completion and regulatory planning toward a defined Phase 3 program, alongside continued MBX 4291 and imapextide development.
Regulatory & Risk Context
MBX has an effective Form S-3 shelf filed on Nov 6, 2025 to offer up to $400,000,000 in securities, including an ATM program for up to $150,000,000 of common stock. This provides flexibility to raise additional capital over time for clinical programs and corporate purposes.
Market Pulse Summary
This announcement combines detailed 2025 financial results with a clear 2026 clinical and corporate roadmap. MBX highlighted pro forma cash and investments of $459.1 million, expected to fund operations into 2029, alongside progressing canvuparatide toward Phase 3 and advancing obesity and PBH programs. Investors may focus on execution against upcoming readouts, the balance between R&D growth and net losses, and any further use of the ATM program for funding.
Key Terms
end-of-phase 2 regulatory
orphan drug designation regulatory
multiple ascending dose medical
open-label extension medical
glp-1/gip/glucagon receptor medical
post-bariatric hypoglycemia medical
at-the-market (atm) facility financial
phase 3 trial medical
AI-generated analysis. Not financial advice.
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA
12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026
Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026
CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted recent corporate progress.
“2025 was a year of continued growth and execution for MBX, highlighted by the clinical validation of our Precision Endocrine Peptide (PEP™) platform,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “Following a successful End-of-Phase 2 meeting with the FDA, we now have a clear path to initiate our Phase 3 trial of once-weekly canvuparatide. We are also advancing a growing obesity pipeline, built on our clinically validated PEPTM platform and designed for once-monthly dosing and improved tolerability. We look forward to a data-rich year ahead and to continuing our pursuit of bringing differentiated and best-in-class medicines to patients.”
Fourth Quarter 2025 and Recent Corporate Highlights
Once-Weekly Canvuparatide for Hypoparathyroidism (HP)
- End-of-Phase 2 FDA meeting for once-weekly canvuparatide completed: FDA feedback supported advancement into a Phase 3 trial and trial design elements have now been selected, including the number of patients, primary endpoint and key secondary endpoints, as well as dose selection, titration schedule and duration of the study. Initiation of the Phase 3 program remains on track for Q3 2026.
- EU Orphan Drug Designation granted for canvuparatide: The European Medicines Agency granted orphan drug designation to canvuparatide for the treatment of chronic hypoparathyroidism, supporting its continued clinical development in Europe.
- MBX expects to present the complete 12-week dataset and one-year follow-up data from the Phase 2 AvailTM trial for once-weekly canvuparatide at a medical conference in Q2 2026.
MBX4291 and Early Pipeline Programs for Obesity
- MBX 4291 advancing through Phase 1: MBX 4291, a GLP-1/GIP co-agonist prodrug designed for potential once-monthly dosing, continues to advance through Phase 1, with 12-week multiple ascending dose data on track to be reported in Q4 2026.
- Obesity portfolio expansion planned in 2026: MBX expects to nominate two additional obesity development candidates enabled by its PEPTM platform, each designed for potential once-monthly dosing with improved tolerability, including an amycretin prodrug targeted for nomination in Q2 2026 and a GLP-1/GIP/glucagon receptor (GCGR) triple-agonist prodrug candidate targeted for nomination in Q3 2026.
Long-Acting Imapextide (MBX 1416) for Post-Bariatric Hypoglycemia (PBH)
- Phase 2a trial of imapextide (MBX 1416) ongoing: Results from the ongoing Phase 2a STEADITM trial of potential once-weekly imapextide for post-bariatric hypoglycemia are expected in Q2 2026.
Corporate
- Board Appointment: In January 2026, the Company announced the appointment of Laurie Stelzer to its Board of Directors as an independent director and Audit Committee Chair, adding strategic, commercial, and financial leadership to support the Company’s advancement toward late-stage development and long-term growth objectives.
- Leadership Addition: In March 2026, MBX announced the appointment of Karen Basbaum, MBA, as Chief Business Officer. Ms. Basbaum brings more than two decades of leadership in corporate strategy, business development, and strategic transactions across the biotechnology and pharmaceutical industries.
- Strengthened Balance Sheet: In February 2026, the Company raised
$85.4 million in net proceeds through its At-the-Market (ATM) facility, with participation from new and existing institutional investors.
Anticipated Milestones
- Canvuparatide
- Q2 2026: Presentation of full Phase 2 AvailTM results at a medical conference, including data from the open-label extension
- Q3 2026: Initiation of Phase 3 trial in chronic hypoparathyroidism
- MBX 4291 and Early Obesity Pipeline
- Q2 2026: Nomination of amycretin prodrug candidate
- Q3 2026: Nomination of GLP-1/GIP/GCGR triple-agonist prodrug candidate
- Q4 2026: Results from 12-week multiple ascending dose portion of Phase 1 trial of MBX 4291
- Imapextide
- Q2 2026: Phase 2a STEADI™ trial results of imapextide for the treatment of post-bariatric hypoglycemia
- Q2 2026: Phase 2a STEADI™ trial results of imapextide for the treatment of post-bariatric hypoglycemia
Fourth Quarter and Full Year 2025 Financial Results
- Cash and Cash Equivalents and Marketable Securities: As of December 31, 2025, MBX Biosciences had cash, cash equivalents and marketable securities of
$373.7 million . Subsequently, on February 4, 2026, the Company raised an additional$85.4 million in net proceeds through its ATM program, resulting in pro forma cash and investments of$459.1 million as of December 31, 2025. Based on its current operating plan, the Company expects the combined cash, cash equivalents and marketable securities balance to fund operations into 2029. - R&D Expenses: Research and development expenses for the three months and full year ended December 31, 2025, were
$19.8 million and$79.2 million , respectively, compared to$15.2 million and$57.4 million for the same periods in 2024. The increases of$4.6 million and$21.8 million respectively were driven by costs associated with the ongoing MBX 4291 Phase 1 clinical trial, the canvuparatide Phase 2 AvailTM clinical trial and preparation activities for a Phase 3 clinical trial in canvuparatide. - G&A Expenses: General and administrative expenses for the three months and full year ended December 31, 2025, were
$6.0 million and$18.9 million , respectively, compared to$3.4 million and$10.8 million for the same periods in 2024. The increases of$2.6 million and$8.1 million , respectively, were driven by increased personnel-related costs as the Company expanded its infrastructure to support its growth in operations and higher professional fees to support operations as a public company. - Net Loss: Net loss for the three months ended December 31, 2025, was
$22.1 million compared to a net loss of$15.6 million for the same period in 2024. Net loss for the full year ended December 31, 2025 was$87.0 million compared to a net loss of$61.9 million for the same period in 2024.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
About MBX’s Proprietary Precision Endocrine Peptide (PEP™) Platform
MBX was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences’ expectations regarding the further advancement of its pipeline of programs in endocrine and metabolic disorders, including timing of initiation of a Phase 3 trial for canvuparatide in Q3 2026 and clinical data presentation in Q2 2026; statements regarding MBX Biosciences’ delivery of differentiated endocrine and metabolic compounds allow patient freedom; MBX Biosicences’ pro forma cash and investments as a result of sales under the ATM program; the contributions of its board of directors; the potential for canvuparatide to be a once-weekly PTH replacement therapy; the expected timing of the Phase 1 readout for MBX 4291 and candidate nominations; the potential for MBX Biosciences to develop therapies for obesity dosed once monthly; the expected timing for the Phase 2a STEADI™ trial results; the ability of MBX 1416 to be a treatment of PBH; and expectations regarding MBX Biosciences’ uses of capital, expenses and financial results, including the anticipated cash runway timing.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; MBX Biosciences’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences’ intellectual property protections; risks related to the competitive landscape for MBX Biosciences’ product candidates; and final audit adjustments and other developments that may arise that would cause MBX Biosciences’ expectations with respect to the estimate of cash, cash equivalents and marketable securities as of December 31, 2025 to differ, perhaps materially, from the financial results that will be reflected in MBX Biosciences’ audited consolidated financial statements for the fiscal year ended December 31, 2025; as well as other risks described in “Risk Factors,” in MBX Biosciences’ Quarterly Report on Form 10-Q for the three months ended September 30, 2025, Annual Report on Form 10-K for the year ended December 31, 2025, as well as subsequent filings filed with the Securities and Exchange Commission (SEC). MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
MBX Biosciences uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact:
George Shea
We. Communications
gshea@wecommunications.com
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
| MBX BIOSCIENCES, INC. | ||||||||||||||||
| SELECTED FINANCIAL INFORMATION | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Statements of Operations Data: | Three months ended December 31, | Year ended December 31, | ||||||||||||||
| (in thousands, except per share and per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 19,759 | $ | 15,223 | $ | 79,159 | $ | 57,415 | ||||||||
| General and administrative | 6,036 | 3,387 | 18,896 | 10,779 | ||||||||||||
| Total operating expenses | 25,795 | 18,610 | 98,055 | 68,194 | ||||||||||||
| Loss from operations | (25,795 | ) | (18,610 | ) | (98,055 | ) | (68,194 | ) | ||||||||
| Interest and other income, net | 3,733 | 3,024 | 11,084 | 6,272 | ||||||||||||
| Net loss | $ | (22,062 | ) | $ | (15,586 | ) | $ | (86,971 | ) | $ | (61,922 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.49 | ) | $ | (0.47 | ) | $ | (2.38 | ) | $ | (5.82 | ) | ||||
| Weighted average number of common shares outstanding used in computation of net loss per common share, basic and diluted | 44,866,468 | 33,392,615 | 36,506,092 | 10,642,954 | ||||||||||||
| (Unaudited) | ||||||||||||||||
| Balance Sheets Selected Financial Data: | December 31, | December 31, | ||||||||||||||
| (in thousands) | 2025 | 2024 | ||||||||||||||
| Cash, cash equivalents and marketable securities | $ | 373,705 | $ | 262,149 | ||||||||||||
| Working capital(1) | 366,044 | 256,235 | ||||||||||||||
| Total assets | 385,144 | 268,535 | ||||||||||||||
| Total liabilities | 15,921 | 11,093 | ||||||||||||||
| Accumulated deficit | (224,476 | ) | (137,505 | ) | ||||||||||||
| Total stockholders’ equity | 369,223 | 257,442 | ||||||||||||||
| (1) Working capital is defined as total current assets less total current liabilities. See our financial statements and the related notes thereto included in our Annual Report on Form 10-K for the Years Ending December 31, 2025 and December 31, 2024 for further details regarding our current assets and current liabilities. | ||||||||||||||||
FAQ
When will MBX (MBX) start the Phase 3 trial for once-weekly canvuparatide?
How much cash does MBX have and how long will it fund operations (MBX)?
What are the near-term data milestones for MBX obesity programs (MBX)?
What were MBX's 2025 R&D and net loss figures and how did they change year-over-year?
When will MBX present full Phase 2 Avail results for canvuparatide and what will be included?
